Skip to content

Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis

Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02227836
Acronym
EoE
Enrollment
8
Registered
2014-08-28
Start date
2014-08-31
Completion date
2017-09-30
Last updated
2019-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Esophagitis

Keywords

Allergy Patch testing, Eosinophilic Esophagitis, EoE

Brief summary

This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.

Detailed description

Patients are referred to Mayo Clinic Rochester with an establish diagnosis of EoE and are nonresponsive to proton pump inhibitor (PPI) medical therapy. Eligible patients will then meet with one of three investigators complete the Mayo Dysphagia Questionaire-30 Day (MDQ-30) following which a standardized Allergy Patch testing (APT) will be conducted. Thereafter, a standard clinically indicated Six Food Elimination Diet treatment completed. Patients will follow up with one of three investigators following the elimination diet who will be blinded to the results of the APT. During this visit responders and nonresponders will be identified and nonresponders will complete a directed elimination diet based on APT results.

Interventions

DEVICEAllergy Patch Testing

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Adults ages 18-90 * Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field (eos per HPF) on index esophageal biopsy * Persistent symptoms and/or greater than or equal to 10 eos per HPF on esophageal biopsy after at least 8 weeks of twice daily PPI therapy

Exclusion criteria

* Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome * Topical swallowed steroids within 8 weeks of study enrollment * Dermatologic conditions precluding application of Finn chambers to the skin for APT * Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of Patch Testingup to 120 hours after application of patch testSensitivity of the patch test will be defined by the number of subjects with total positive APT reactions correlated to histologic findings

Countries

United States

Participant flow

Participants by arm

ArmCount
Allergy Patch Testing APT
Patient will undergo APT testing per the following protocol: * 2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back. * Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits * The patches will be removed at 48 hours, and results read at 72 and 120 hours after application. * Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles).
8
Total8

Baseline characteristics

CharacteristicAllergy Patch Testing APT
Age, Continuous43 years
STANDARD_DEVIATION 11
Allergic history7 Participants
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
8 participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
0 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

Primary

Sensitivity of Patch Testing

Sensitivity of the patch test will be defined by the number of subjects with total positive APT reactions correlated to histologic findings

Time frame: up to 120 hours after application of patch test

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Allergy Patch Testing APTSensitivity of Patch Testing1 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026